Navidea announced the launch of Lymphoseek (technetium Tc 99m tilmanocept) Injection for use in lymphatic mapping procedures that are performed to help in the diagnostic evaluation of potential cancer spread for patients with breast cancer and melanoma. Lymphoseek was approved by the FDA in March 2013.
Lymphoseek is a novel, receptor-targeted, small-molecule radiopharmaceutical designed to identify the lymph nodes that drain from a primary tumor, which have the highest probability of harboring cancer.
Lymphoseek Injection is supplied as a preparation kit that includes five vials of tilmanocept powder 250mg, five vials of diluent, five labels for shields, and twenty-five labels for vials and individual syringes.
For more information call (800) 793-0079 or visit the Lymphoseek website.
This article originally appeared on MPR